Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Filters applied. Clear all
. 2017 Jan;19(1):298-312.
doi: 10.1208/s12248-016-0009-9. Epub 2016 Nov 7.

Clarithromycin, Midazolam, and Digoxin: Application of PBPK Modeling to Gain New Insights Into Drug-Drug Interactions and Co-medication Regimens

Affiliations

Clarithromycin, Midazolam, and Digoxin: Application of PBPK Modeling to Gain New Insights Into Drug-Drug Interactions and Co-medication Regimens

Daniel Moj et al. AAPS J. .

Abstract

Clarithromycin is a substrate and mechanism-based inhibitor of cytochrome P450 (CYP) 3A4 as well as a substrate and competitive inhibitor of P-glycoprotein (P-gp) and organic anion-transporting polypeptides (OATP) 1B1 and 1B3. Administered concomitantly, clarithromycin causes drug-drug interactions (DDI) with the victim drugs midazolam (CYP3A4 substrate) and digoxin (P-gp substrate). The objective of the presented study was to build a physiologically based pharmacokinetic (PBPK) DDI model for clarithromycin, midazolam, and digoxin and to exemplify dosing adjustments under clarithromycin co-treatment. The PBPK model development included an extensive literature search for representative PK studies and for compound characteristics of clarithromycin, midazolam, and digoxin. Published concentration-time profiles were used for model development (training dataset), and published and unpublished individual profiles were used for model evaluation (evaluation dataset). The developed single-compound PBPK models were linked for DDI predictions. The full clarithromycin DDI model successfully predicted the metabolic (midazolam) and transporter (digoxin) DDI, the acceptance criterion (0.5 ≤ AUCratio,predicted/AUCratio,observed ≤ 2) was met by all predictions. During co-treatment with 250 or 500 mg clarithromycin (bid), the midazolam and digoxin doses should be reduced by 74 to 88% and by 21 to 22%, respectively, to ensure constant midazolam and digoxin exposures (AUC). With these models, we provide highly mechanistic tools to help researchers understand and characterize the DDI potential of new molecular entities and inform the design of DDI studies with potential CYP3A4 and P-gp substrates.

Keywords: PBPK; clarithromycin; digoxin; dose; drug interaction; midazolam.

Similar articles

See all similar articles

Cited by 6 articles

See all "Cited by" articles

References

    1. J Clin Pharmacol. 2009 Mar;49(3):351-9 - PubMed
    1. Biochem Pharmacol. 1999 Mar 1;57(5):465-80 - PubMed
    1. Xenobiotica. 2007 Oct-Nov;37(10-11):1225-56 - PubMed
    1. Am Heart J. 1978 Oct;96(4):507-11 - PubMed
    1. Drug Metab Dispos. 1997 May;25(5):623-30 - PubMed

MeSH terms

Feedback